Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.
FLT3 tyrosine kinase domain mutations (FLT3/TKDs) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike FLT3 internal tandem duplications (FLT3/ITDs) that have a poor prognosis. Whilst FLT3/ITD+ cells are more susceptible to the cytotoxic effects of FLT3 inhibitors than...
Auteurs principaux: | Mead, A, Gale, R, Kottaridis, P, Matsuda, S, Khwaja, A, Linch, D |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
2008
|
Documents similaires
-
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia.
par: Mead, A, et autres
Publié: (2007) -
A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML
par: Knapper, S, et autres
Publié: (2017) -
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.
par: Gale, R, et autres
Publié: (2008) -
Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia
par: Aziz Nazha, et autres
Publié: (2012-08-01) -
Neurotrophin-3 and FLT3 Tyrosine Kinase Receptor in Perinatal Life
par: Ariadne Malamitsi-Puchner, et autres
Publié: (2005-01-01)